Table 4.
Diagnostic accuracy of 11q13 overexpression for nodal status in OSCC
| Study | Nodal metastasisa | Threshold for overexpression | Overexpression | Primary antibody | OR (95 % CI) | p value | NPV (%) | PPV (%) | AC (%) | SE | SP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Huang et al. | 126/264, 48 % | 10 % staining | 97/264, 37 % | Monoclonal, SP4 | 2.48 (1.48–4.15) | 0.001 | 73 | 48 | 61 | 62 | 60 |
| Prapinjumrune et al. | 24/60, 40 % | 29.2 % staining | 40/60, 66 % | Monoclonal, 1/FADD | 4.00 (1.14–14.09) | 0.025 | 44 | 83 | 60 | 50 | 80 |
| Shah et al. | 44/135, 33 % | 10 % staining | 43/135, 32 % | Monoclonal, P2D11F11 | 1.35 (0.63–2.90) | 0.435 | 70 | 37 | 59 | 36 | 70 |
| Maahs et al. | 23/45, 51 % | 1 % staining | 15/45, 33 % | N.A. | 1.71 (0.49–6.03) | 0.401 | 53 | 60 | 56 | 39 | 73 |
| Rodolico et al. | 13/97, 13 % | 1 % staining | 65/97, 67 % | Monoclonal, DCS-6 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
| Miyamoto et al. | 8/41, 20 % | 10 % staining | 27/41, 66 % | Monoclonal, DCS-6 | 1.71 (0.30–9.87) | 0.546 | 36 | 75 | 44 | 22 | 86 |
| Takes et al. | 33/52, 63 % | 5 % staining | 30/52, 58 % | Monoclonal, DCS-6 | 0.70 (0.22–2.23) | 0.546 | 32 | 60 | 48 | 54 | 37 |
| Goto et al. | 18/41, 44 % | 33 % staining | 14/41, 34 % | Monoclonal, DCS-6 | 3.60 (0.93–13.95) | 0.064 | 67 | 64 | 66 | 50 | 78 |
| Kuo et al. | 53/88, 60 % | 10 % staining | 73/88, 83 % | Polyclonal, N.A. | 1.41 (0.46–4.30) | 0.550 | 47 | 62 | 59 | 85 | 20 |
| Bova et al. | 34/147, 23 % | 10 % staining | 100/147, 68 % | Monoclonal, D1-GM | 3.43 (1.23–9.54) | 0.018 | 37 | 85 | 48 | 29 | 89 |
OR odds ratio, CI confidence interval, G/C gene/chromosome, NPV negative predictive value, PPV positive predictive value, AC accuracy, SE sensitivity, SP specificity, N.A. not available
aHistologically proven nodal metastasis